Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer

BACKGROUND: Canfosfamide is a novel glutathione analog activated by glutathione S-transferase P1-1. This study evaluated the safety and efficacy of canfosfamide in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum resistant ovarian cancer. Patients with platinum resist...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kavanagh, John J, Levenback, Charles F, Ramirez, Pedro T, Wolf, Judith L, Moore, Carla L, Jones, Marsha R, Meng, Lisa, Brown, Gail L, Bast, Robert C
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2010
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2851575/
https://ncbi.nlm.nih.gov/pubmed/20222977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-3-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars